Genomics Reporting Implementation Guide
3.0.1-SNAPSHOT - Ballot International flag

Genomics Reporting Implementation Guide, published by HL7 International / Clinical Genomics. This guide is not an authorized publication; it is the continuous build for version 3.0.1-SNAPSHOT built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/genomics-reporting/ and changes regularly. See the Directory of published versions

: PGxRecEx04 - JSON Representation

Raw json | Download


{
  "resourceType" : "Task",
  "id" : "PGxRecEx04",
  "meta" : {
    "profile" : [
      🔗 "http://hl7.org/fhir/uv/genomics-reporting/StructureDefinition/followup-recommendation"
    ]
  },
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Task PGxRecEx04</b></p><a name=\"PGxRecEx04\"> </a><a name=\"hcPGxRecEx04\"> </a><a name=\"PGxRecEx04-en-US\"> </a><p><b>status</b>: Requested</p><p><b>intent</b>: proposal</p><p><b>code</b>: <span title=\"Codes:{http://loinc.org LA26422-8}\">Decrease dose</span></p><p><b>description</b>: For escitalopram, a 50% reduction in starting dose is recommended with therapeutic drug monitoring to guide dose adjustment or select an alternate drug not predominantly metabolized by CYP2C19. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/. If CYP2D6 genotyping is available, refer to the current guidelines for dosing recommendations.</p><p><b>for</b>: <a href=\"Patient-CGPatientExample01.html\">Adam B. Everyman  Male, DoB: 1951-01-20 ( Medical Record Number: m123\u00a0(use:\u00a0usual,\u00a0))</a></p><p><b>reasonReference</b>: <a href=\"Observation-TxImp04.html\">Poor metabolizer</a></p></div>"
  },
  "status" : "requested",
  "intent" : "proposal",
  "code" : {
    "coding" : [
      {
        "system" : "http://loinc.org",
        "code" : "LA26422-8",
        "display" : "Decrease dose"
      }
    ]
  },
  "description" : "For escitalopram, a 50% reduction in starting dose is recommended with therapeutic drug monitoring to guide dose adjustment or select an alternate drug not predominantly metabolized by CYP2C19. Refer to current guidelines for dosage and recommendations at https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/. If CYP2D6 genotyping is available, refer to the current guidelines for dosing recommendations.",
  "for" : {
    🔗 "reference" : "Patient/CGPatientExample01"
  },
  "reasonReference" : {
    🔗 "reference" : "Observation/TxImp04",
    "display" : "Poor metabolizer"
  }
}